Joint Statement on Strengthening the Antibiotic R&D Pipeline by Rewarding Innovation

  20 November 2021

The emerging threat of antimicrobial resistance (AMR) for public health worldwide is not only
concerning during the COVID-19 pandemic, but will become even more alarming after the current
global health crisis. To combat this threat, no single actor or actor group can deliver a solution
alone. A partnership approach with both the public and private sector is essential to successfully
address the public health impact of AMR. There is a high unmet need for innovative antibiotics that
either overcome resistances and/or offer novel treatment options to yet untargeted pathogens and
to serve the needs of particularly vulnerable populations, especially children and neonates. In addition, for already approved antibiotics the access-to-market transition and their rapid availability and
accessibility in high-burden countries must be much better ensured. Lastly, this goes together with
an appropriate use of antibiotics to avoid the emergence of new resistances (antibiotic stewardship).

Further reading: GARDP
Author(s): GARDP
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!